Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
P/E ratio for Xilio Therapeutics, Inc. (XLO)
P/E ratio as of 2023: -0.20
According to Xilio Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.20. At the end of 2022 the company had a P/E ratio of -0.84.
P/E ratio history for Xilio Therapeutics, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.20 |
| 2022 | -0.84 |
| 2021 | -5.89 |
| 2020 | -7.96 |
| 2019 | -25388.66 |